INTRODUCTION FTY720 is a new type of immunosuppressant that induces a transient, reversible lymphopenia by trapping lymphocytes in the secondary lymphoid organs and thereby keeping them out of the circulation. This mode of immunosuppression is unique amongst pharmacological immunosuppressants, and has made FTY720 the subject of intense interest, both from a therapeutic and a mechanistic/physiological perspective.
Lymphopenia induced by FTY720 is dependent on the phosphorylation of the compound by sphingosine kinase 2 (SphK2) (Billich et al., 2003; Zemann et al., 2006) . The phosphorylated compound acts as an agonist at four of the five sphingosine 1-phosphate (S1P) receptors, a family of G-protein coupled receptors that respond to extracellular S1P (Brinkmann et al., 2002; Mandala et al., 2002) .
Activation (agonism) of the S1P 1 receptor is responsible for sequestration of T-cells in the peripheral lymphoid organs, demonstrated with the observations that a range of S1P 1 -selective agonists can induce lymphopenia, that this is reversible with an S1P 1 antagonist, and that S1P 1 -deficient lymphocytes are resistant to the effects of FTY720 (Matloubian et al., 2004; Pan et al., 2006; Sanna et al., 2006) . Two models have been put forward to explain exactly how S1P 1 agonists induce lymphopenia (Brinkmann, 2007; Rosen et al., 2008) : in one model activation of S1P 1 receptors on endothelial cells exposed to the blood or lymph results in the closure of endothelial gates through which lymphocytes exit the lymph nodes; the other model invokes lymphocyte migration from the low S1P environment of the lymph nodes towards the higher S1P concentration of the blood or lymph, requiring stimulation of their S1P 1 receptors. In a simple interpretation of this model, the presence of FTY720-phosphate (FTY-P) in lymph nodes disrupts this gradient. However, another interpretation is derived from the observation that FTY-P acts as a super-agonist of S1P 1 , promoting internalization This article has not been copyedited and formatted. The final version may differ from this version. and degradation of the receptor. This impairs the ability of lymphocytes to respond to the proposed S1P gradient (Gonzalez-Cabrera et al., 2007; Oo et al., 2007) . S1P receptor modulating compounds like FTY-P have found application in a wide variety of experimental settings, which include immunosuppression during organ transplant (Brinkmann, 2007; Pan et al., 2006) , treatment of autoimmune conditions (Fujino et al., 2003; Maki et al., 2005) , recovery after ischaemia/reperfusion injury (Hofmann et al., 2009) , and as a means of increasing endothelial barrier function (Sanna et al., 2006) . In the clinic, FTY720 has been trialed both in kidney transplant and multiple sclerosis patients (Brinkmann, 2007) . The trials in transplant patients failed to show any improvement in efficacy over the current standard of care, but the compound has showed great promise in Phase III trials, in patients with relapsingremitting multiple sclerosis (Cohen et al., 2010; Kappos et al., 2010) . Fewer relapses were reported with FTY720 than with the current treatment, intramuscular intereferon β (Cohen et al., 2010) .
The FTY720 analogue AAL(R) has been used in a number of studies, because its chiral enantiomer AAL(S) is not a substrate for SphK2, and therefore acts as a useful control for effects of the compound that are not attributed to its phosphorylation (Brinkmann et al., 2002; Don et al., 2007; Kiuchi et al., 2000) . As FTY720 and AAL(R) are very similar compounds, they have been used interchangeably. In this research paper, we show that AAL(R) is a much better substrate for SphK2 than FTY720, which translates into a faster rate of phosphorylation by cultured cells and in whole blood, and almost complete phosphorylation in living mice. Phosphorylation of FTY720 occurs much more rapidly in rodent than human blood, suggesting that This article has not been copyedited and formatted. The final version may differ from this version. 6 AAL(R) would prove significantly more effective than FTY720 as a sphingosine 1-phosphate receptor agonist in humans.
MATERIALS AND METHODS

Materials
FTY720 was purchased from Chemicon, whilst AAL(R) was a gift from Professor Hugh Rosen, The Scripps Research Institute. AAL-P to use as a standard for mass spectrometry was prepared by chemical phosphorylation: The amino group of AAL was protected (Boc2O, NaHCO3, 56%), then reaction with N,N-diisopropyl phosphoramidite dichloride and 5-ethylthio-1H-tetrazole, followed by oxidation with hydrogen peroxide, gave protected AAL-P in 19% yield. The compound was deprotected with trifluoroacetic acid. DhSph was purchased from Avanti Polar
Lipids. Synthesis of 3-deoxy-dhSph has been reported previously (Lim et al., 2004) .
Cell culture and viability assays
Jurkat cells and primary splenocytes were cultured in RPMI1640 medium supplemented with 10% foetal bovine serum (FBS), 2 mM L-glutamine, and penicillin/streptomycin solution. The human microvascular endothelial cell line HMEC-1 (Ades et al., 1992) was cultured in MCDB131 medium supplemented with 10% FBS, glutamine, and antibiotics. Rat splenocytes were isolated by crushing the spleen between frosted glass slides and filtering through a 70 μM filter, followed by two rounds of red cell lysis in 0.17 M NH 4 Cl, 10 mM NaHCO 3 , 0.1 mM EDTA, for 5 min on ice. Isolated splenocytes were resuspended at a density of 1.5 x 10 6 viable cells/mL in complete RPMI medium, cultured in the presence of AAL(R), AAL(S) or FTY720 for 20 h, then stained with PI for flow cytometry. For MTT assays, cells
This article has not been copyedited and formatted. The final version may differ from this version. To assay phosphorylation of compounds in whole blood, human or rat blood was collected into heparin-coated tubes, then mixed 1:1 with RPMI1640 medium. One nmole FTY720 or AAL(R) was added directly to 250 μL blood/RPMI mix, and incubated at 35 °C for the indicated times. Reactions were stopped with the addition of 1 mL ice-cold methanol, and the mixture was cleared by centrifuging at 21,000 g for 15 min. The insoluble pellets were re-extracted by sonicating in 1 mL methanol.
The supernatants from both steps were combined in 4 mL glass tubes, dried down in a Speedivac, and the extracts were resuspended in 200 μL 80% methanol/20% water This article has not been copyedited and formatted. The final version may differ from this version. (LC mobile phase). Extraction efficiency was determined by spiking blood with compounds, then immediately extracting.
Sphingosine kinase assays
The radioactive kinase assays were based on published methods (Olivera et al., 2000; Siow and Wattenberg, 2007) . Kinase assays were set up in 50 mM Tris, pH 7.4, 150 mM NaCl, 10 mM MgCl 2 , 1 mM DTT, 2 mM ATP, 0.1% fatty acid free BSA, and 5
μCi/reaction radioactively labeled 32 P-ATP (Perkin Elmer). Reactions (0.1 mL) were started with the addition of recombinant human SphK2, produced in insect cells (Biomol). The final enzyme concentration was 0.2 μg/mL for dhSph and 3-deoxydhSph, and 1 μg/mL for AAL(R) and FTY720. Reactions were run for 30 min at 35
°C for dhSph, 3-deoxy-dhSph, and AAL(R), and 150 min in the case of FTY720.
Note that the different enzyme concentrations and times were used to ensure that enzyme, and not available substrate, was rate limiting. Reactions were stopped with the addition of 350 μL methanol/HCl (150:1), followed by 250 μL 2M KCl, and 350 μL chloroform. Tubes were vortexed, then microfuged at 14,000 rpm to resolve the phases. The upper aqueous phase was discarded, and 4 μL of the (lower) organic phase was spotted on to Silica Gel 60 TLC plates (Fluka). TLC plates were resolved in butanol/acetic acid/water (3:1:1), then exposed to Fuji Imaging Plates and imaged with a Fuji FLA7000 phosphorimager. The concentration of product in each spot was derived from a standard curve constructed with the 32 P-ATP reaction mix.
Lipid phosphatase assay
To prepare radiolabelled FTY-P and AAL-P, solutions of 50 μM FTY720 or AAL(R)
were phosphorylated in kinase assay buffer containing 10 μCi/400 μL reaction recombinant SphK2. Reactions were stopped and extracted with addition of 400 μL methanol, 40 μL 3M NaOH, and 400 μL chloroform. Tubes were vortexed, phases were separated by centrifugation, and the upper aqueous phase, containing the radiolabelled phosphates, was transferred to a new tube. This aqueous extract was reextracted by adding 80 μL concentrated HCl and 400 μL chloroform, this time discarding the aqueous phase and retaining the lower organic phase. This method effectively separates the sphingoid bases from their phosphates (Maceyka et al., 2007) . The organic extract was dried down and resuspended in 400 μL 50 mM Tris, pH 7.4, 150 mM NaCl, 0.1% fatty acid free BSA, and the concentration of the radiolabelled phosphate was measured by resolving the resuspended compound on TLC and quantification of FTY-P or AAL-P spots with a phosphorimager.
To assay dephosphorylation, HMEC-1 cells were seeded at a density of 2 x 10 5 cells/well, in a 24-well plate. On the following day, the medium was replaced with 0.3 mL fresh growth medium containing 100 nM radiolabelled FTY-P or AAL-P.
Samples (2.5 μL) were removed at indicated times and spotted onto a TLC plate, then resolved and imaged as described above.
In vivo measurement of compounds and circulating lymphocytes AAL(R) or FTY720 were administered by intra peritoneal injection, in 0.1 mL sterile water, to groups of 4 (per treatment) C57BL6 mice. Mice were euthanased, and blood was drawn by cardiac puncture 18 h after dosing. A 0.1 mL aliquot of blood from each mouse receiving 0.3 mg/kg AAL(R) or FTY720 was immediately mixed with 0.4 mL ice cold methanol, and the samples were processed for mass spectrometry as This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
AAL(R) but not FTY720 treatment triggers SphK2-dependent cell death
We have previously shown that phosphorylation of AAL(R) by SphK2 is required for this compound to induce a loss of viability in cultured murine splenocytes, based on two observations: firstly AAL(R) was much more efficient than its nonphosphorylatable enantiomer, AAL(S), at inducing loss of viability; secondly, splenocytes derived from SphK2 knockout mice were resistant to AAL(R) (Don et al., 2007) . These findings led us to propose that a specific apoptotic response is triggered by excessive intracellular accumulation of AAL(R)-phosphate (AAL-P). To our surprise, we have found that FTY720 is much less potent than AAL(R), and equipotent with AAL(S), at inducing loss of viability in cultured mouse splenocytes ( Figure 1A ). FTY720 was also less efficient than AAL(R) at inducing apoptosis in the triggers a SphK2-dependent apoptotic response, we investigated whether AAL-P accumulates inside cells to a greater extent than FTY-P.
AAL(R) is more rapidly phosphorylated than FTY720
We found that AAL(R) is phosphorylated much more rapidly than FTY720 by cultured Jurkat cells, using liquid chromatography mass spectrometry (LC-MS/MS) ( Figure 3A ). We therefore compared the phosphorylation rate for these compounds in whole blood, which is rich is sphingosine kinase 2 activity (Billich et al., 2003) . The rate of phosphorylation in human blood was 8.9-fold faster with AAL(R) than with FTY720 as substrate ( Figure 3B and Table 1 ). Both compounds were phosphorylated much more rapidly in rat blood, when compared to human blood: the rate of phosphorylation was 35-fold higher for FTY720 and 27-fold higher for AAL(R), in rat versus human blood. The more rapid conversion of FTY720 by mouse or rat blood, compared to human blood, has been reported previously, although without quantification of the difference in rate (Billich et al., 2003) . The difference was attributed to the higher SphK2 activity of rodent blood compared to human blood, This article has not been copyedited and formatted. The final version may differ from this version. We next investigated whether AAL(R) is a better substrate for SphK2 than FTY720, using an in vitro reaction with recombinant human SphK2 ( Figure 4A ). The enzyme turnover rate was 7.9 times higher with AAL(R) as the substrate, whilst the ability of the enzyme to bind the substrate (measured as K m ) was very similar (Table 2 ). This difference in phosphorylation rate is very similar to that observed with whole human blood (8.9-fold higher with AAL(R) as substrate). Similar results were seen when lysates of HEK293 cells overexpressing human SphK2 were used as the source of SphK2 activity: the turnover rate was 14 times higher with AAL(R) than with FTY720 as the substrate, whilst the K m was similar (7.4 μM for AAL(R); 13.2 μM for FTY720). These results indicate that whilst there appears to be no difference in the affinity of SphK2 for the two substrates, the active site is better able to turnover AAL(R) than FTY720.
The key structural difference between FTY720 and AAL(R) is a hydroxymethyl to methyl substitution on the quaternary (second) carbon of the headgroup ( Figure 4C ), suggesting that the presence of this second hydroxyl group interferes with catalysis or release of the product. In the natural substrates sphingosine and dihydrosphingosine (dhSph), a second hydroxyl group located on the third carbon of the acyl chain is not accessible for phosphorylation by sphingosine kinases. To gain some insight into whether this 3-OH group influences the phosphorylation rate or substrate affinity, we determined the Michaelis-Menten kinetics for phosphorylation of dhSph and 3-deoxydhSph ( Figure 4D ) by SphK2 ( Figure 4B and reduced the enzyme turnover rate and slightly increased the K m , but the effects were not dramatic, indicating that the 3-OH group plays a minor role in substrate recognition and turnover by SphK2.
FTY720 is dephosphorylated faster than AAL(R)
The steady-state level of FTY-P achieved in living organisms is a function not only of phosphorylation, but also of dephosphorylation. As FTY-P is membrane impermeable, a likely candidate organ for dephosphorylation of circulating FTY-P is the endothelium, which on the other hand has very little SphK2 activity and is therefore not likely to contribute significantly to the compound's phosphorylation (Anada et al., 2007) . FTY-P is a membrane impermeable compound and recent evidence indicates that it may be dephosphorylated extracellularly by endothelial lipid phosphate phosphatases, specifically subtypes 1a and 3 (Mechtcheriakova et al., 2007; Yamanaka et al., 2008) . In order to determine whether there are any differences in the ability of lipid phosphatases to dephosphorylate the two compounds, we tested the ecto-phosphatase activity of cultured human endothelial cells towards both FTY-P and AAL-P ( Figure 5 ). In direct contrast to the rate of phosphorylation by SphK2, the rate of dephosphorylation was faster with FTY-P. Using a one phase exponential decay model to fit the data, the difference in dephosphorylation rate was 1.5, 1.6, and 2.9-fold (faster in the case of FTY-P) in three separate experiments, and was statistically significant (P < 0.001, sum-of-squares test).
AAL(R) is more fully phosphorylated in vivo.
Our in vitro results indicated that AAL(R) should be more completely phosphorylated than FTY720, at steady state, in vivo. To test this, we administered a single 0.3 mg/kg This article has not been copyedited and formatted. The final version may differ from this version. dose of AAL(R) or FTY720 to mice, and measured the amount of AAL(R) and AAL-P, or FTY720 and FTY-P, in the blood 18 h later ( Figure 6 ). For AAL(R), 3.7 ± 1.3 % of the compound remained unphosphorylated (i.e. 96% phosphorylated), whilst for FTY720, this was 19.1 ± 3.1 % (81% phosphorylated), a statistically significant difference (P < 0.001, unpaired t-test). Measurements of FTY720 phosphorylation in mice at 2 h (82 %) and 6 h (83 %) indicated that a steady state balance was rapidly achieved, and whilst the total amount of compound in blood declined over time, the proportion of phosphorylated compound remained steady.
DISCUSSION
Induction of lymphopenia with FTY720 is dependent on stimulation of the S1P 1 receptor by FTY-P. The potency (EC 50 ) and efficacy (E max ) for AAL-P, FTY-P and S1P on the human S1P 1 receptor are essentially identical (Brinkmann et al., 2002) . shown that apoptosis triggered by AAL(R) proceeds through mitochondrial depolarisation (not shown), but the precise nature of the intracellular target for AAL-P that triggers apoptosis is currently unknown. AAL(R) and FTY720 both trigger a SphK2-independent apoptotic pathway at concentrations around 10 μM. Apoptosis induced with FTY720 forms the basis for its anti-cancer properties, and is believed to occur through activation of the broad spectrum serine/threonine phosphatase PP2A, at least in leukaemia cells (Liu et al., 2008; Matsuoka et al., 2003; Neviani et al., 2007) .
Our results are in agreement with those of others, who have shown that FTY720 does not need to be phosphorylated in order to induce apoptosis in leukaemia cells (Liu et al., 2008; Neviani et al., 2007) . Neither the SphK2-dependent nor the SphK2-independent apoptotic pathway are relevant to immunosuppression, since these pathways are activated at concentrations of the drug that are one to two orders of magnitude higher than the concentration required to achieve effective immunosuppression in humans or rodents.
This article has not been copyedited and formatted. The final version may differ from this version. There are two structural differences between AAL(R) and FTY720 ( Figure 4C ): the introduction of an ether linkage (replacing a carbon) between the lipid tail and the aromatic ring in AAL(R) , and elimination of one of the FTY720 hydroxyl headgroups. It has been shown previously (Kiuchi et al., 2000) that introduction of the ether linkage into FTY720 does not improve, or significantly alter, its potency as an inducer of lymphopenia. We therefore conclude that elimination of one of the hydroxyl groups improves catalysis by SphK2. The hydroxyl group on the third carbon of dhSph does not slow down its phosphorylation by SphK2, relative to 3-deoxy-dhSph ( Figure 4B ), indicating that it is the position of the second hydroxyl group in FTY720 that interferes with catalysis. It is likely that the presence of two hydroxyl groups in FTY720, both accessible to the SphK2 catalytic site, interferes with release of the product or the transfer of phosphate from ATP.
In rodents a cycle of phosphorylation and dephosphorylation maintains an equilibrium between FTY720 and FTY-P in the blood, with 20-30% of the compound in the nonphosphorylated form (Brinkmann et al., 2002; Mandala et al., 2002 ). In the current study, we show that when AAL(R) is used, the equilibrium is shifted in favour of the phosphate (Figure 6 ), and this gives rise to an increase in potency. For this reason, AAL(R) is probably superior, compared to FTY720, as a research tool for determining the effects the sphingosine 1-phosphate receptor agonists on animal physiology and pathophysiology, especially given the availability of a chemically identical, non-phosphorylatable control compound in the form of the S-enantiomer.
We note that asymmetric synthesis of AAL(R) or AAL(S) is not difficult, and can be achieved by starting with the chiral headgroup and adding the lipophilic portion of the This article has not been copyedited and formatted. The final version may differ from this version. In human patients FTY720 phosphorylation appears to be rate limiting for efficacy.
Human blood possesses a much lower intrinsic SphK2 activity than rodent blood (Billich et al., 2003) , resulting in a much slower rate of phosphorylation for both FTY720 and AAL(R) ( Figure 3B) . Results with human patients indicate that the equilibrium between FTY720 and its phosphate rests more heavily in favour of dephosphorylation: the plasma concentration of FTY-P drops below that of FTY720
12 -24 h after a single 5 mg dose of FTY720, and thereafter FTY-P declines as a proportion of the FTY720 concentration (Kovarik et al., 2009; Kovarik et al., 2008) .
On this basis one would predict that AAL(R) would achieve effective immunosuppression at a significantly lower dose in humans than FTY720.
Lymphopenia in humans is achieved with doses of FTY720 at or above 1 mg/day. At this dose the steady state FTY720 concentration in plasma reaches 5.7 ng/mL (18.6 nM). More effective lymphopenia is achieved at 2.5 mg/day (steady state FTY720 concentration of 36.5 nM in plasma) (Brinkmann, 2007; Kahan et al., 2003) . At this concentration FTY720 may have effects that are not dependent on its phosphorylation, such as inhibition of cytosolic phospholipase A 2 , with consequently inhibition of prostaglandin and prostacyclin synthesis (Payne et al., 2007) , or inhibition of Protein Kinase C isoforms (Sensken and Graler, 2010) .
In summary, in this paper we report that the R enantiomer of the FTY720 derivative 2-amino-1,3-propanediol is a much better substrate for SphK2 than FTY720 itself.
This results from a faster enzyme turnover, rather than higher affinity, and leads to a Data points were fitted to a one phase decay model using GraphPad PRISM. Amount of AAL(R) and AAL-P, or FTY720 and FTY-P, in the blood, 18 h after intra peritoneal administration of 0.3 mg/kg AAL(R) or FTY720 to C57BL6 mice (n = 4).
Free base (shaded bars) refers to AAL(R) and FTY720, whilst base phosphate (clear bars) refers to AAL-P and FTY-P.
This article has not been copyedited and formatted. The final version may differ from this version. Table 1 . Rate of FTY720 and AAL(R) phosphorylation in whole blood.
Phosphorylation rates were calculated using only the linear portion of the phosphorylation curves shown in Figure 3B . Units are nmoles product/h/mL blood (± standard error).
FTY720 AAL(R)
Human blood 0.056 ± 0.001 0.496 ± 0.014
Rat blood 1.93 ± 0.040 13.3 ± 1.13
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